Therefore, for the purposes of C1739, CMS considers the start of the device pass-through payment status eligibility period to be January 1, 2025, and, as such, CMS does not agree with the applicant that the device category code for C1739 should be withdrawn, and a new code issued effective January 1, 2026
Cardiovascular outcome trials evaluating novel agents that target multiple pathways including combinations of GLP-1 agonism, GIP agonism, glucagon receptor agonism and amylin analogues are ongoing and will help define the next generation of obesity treatments
Structured meal planning , consistent exercise, adequate sleep, and stress management remain the foundation of weight management even when using the most effective medications available
However, human studies have not yet examined this mechanism in detail